<DOC>
	<DOCNO>NCT00040144</DOCNO>
	<brief_summary>The purpose study determine safety antiviral HBV activity ACH126 , 433 ( b-L-Fd4C ) treatment adult lamivudine-resistant chronic Hepatitis B .</brief_summary>
	<brief_title>Safety Antiviral Study ACH126 , 433 ( b-L-Fd4C ) Adults With Lamivudine-resistant Chronic Hepatitis B</brief_title>
	<detailed_description>Evaluation safety antiviral activity 3 dose level ACH126 , 443 twelve week treatment population describe .</detailed_description>
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis , Chronic</mesh_term>
	<mesh_term>Hepatitis B</mesh_term>
	<mesh_term>Hepatitis B , Chronic</mesh_term>
	<mesh_term>Lamivudine</mesh_term>
	<criteria>Inclusion Criteria Adults ≥ 18 year age Chronic HBV infection , know HbsAg positive ≥ 6 month On lamivudine , either 100 150 mg daily treatment chronic hepatitis B infection Exhibit 23 log decrease HBV DNA level follow rebound least 1.5 log HBV DNA Achieved HBV DNA level &lt; 10,000 copies/mL HBV DNA least 2 occasion rebound &gt; 100,000 copies/mL HBV DNA , Have demonstrable 3TC resistant genotype regardless treatment history . HBeAG positive HIV negative Serum ALT ≥1.5 ≤10x time upper limit normal HGB ≥10g/dl HCT ≥30 % ( absence blood transfusion erythropoietin treatment precede two week ) Platelet count &gt; 75,000/mm ( ^3 ) , ( absence ongoing GCSF therapy ) Serum creatinine &lt; 1.1 time upper limit normal ( ULN ) Negative radiologic screen test ( ultrasound , CT scan MRI ) hepatocellular carcinoma ( HCC ) within 6 month prior entry PT/INR &lt; 2 Subjects reproductive capability must utilize approve form birth control All woman childbearing capability must negative serum urine pregnancy test ( minimum sensitivity 24 IU/L bHCG ) within 72 hour prior start study medication Subjects must able provide write informed consent Subject must available followup period 20 week Exclusion Criteria HIV infection Hepatitis C coinfection Alcohol abuse Pregnancy breastfeed Inability tolerate oral medication Any clinical condition prior therapy , Investigator 's opinion , would make subject unsuitable study unable comply dose requirement Use investigational drug Patients decompensated liver disease Use concomitant herbal treatment</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2009</verification_date>
	<keyword>E-Antigen positive ,</keyword>
	<keyword>Lamivudine-Resistant Chronic Hepatitis B ,</keyword>
	<keyword>Achillion</keyword>
</DOC>